Eli Lilly Q1 FY26: where the revenue came from and where it went
The whole income statement of Eli Lilly for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2026
- Reported
- Apr 30, 2026
Revenue$19.8B
+56% year over year
Gross profit$16.2B
82% margin
Operating profit$8.9B
45% margin
Net profit$7.4B
37% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 19.8 | 100% | +56% |
| Mounjaro | 8.7 | 44% | +125% |
| Zepbound | 4.2 | 21% | +80% |
| Other revenue | 1.8 | 9% | |
| Verzenio | 1.3 | 6% | +12% |
| Jardiance | 1.1 | 6% | +10% |
| Other oncology | 1.0 | 5% | +22% |
| Trulicity | 0.9 | 5% | −16% |
| Cardiometabolic health | 0.9 | 4% | −4% |
| Cost of revenue | −3.6 | 18% | |
| Gross profit | 16.2 | 82% margin | −1pp |
| SG&A | −2.9 | 15% | −5pp |
| Other | −4.4 | 22% | +0pp |
| Operating profit | 8.9 | 45% margin | +16pp |
| Interest & other costs | −0.1 | ||
| Tax | −1.5 | ||
| Net profit | 7.4 | 37% margin | +16pp |
123 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest